RecruitingEarly Phase 1NCT06693960

Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach

Sponsor

Washington State University

Enrollment

16 participants

Start Date

Sep 26, 2024

Study Type

INTERVENTIONAL

Conditions

Interaction

Summary

The purpose of this clinical trial is to determine how the supplement oregano affects how the body metabolizes pharmaceutical drugs.

Eligibility

Min Age: 18 YearsMax Age: 64 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Drug cocktail and Oregano for people with interaction. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 64 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTOregano

Oil of oregano administered as a softgel (180 mg).

DRUGDrug cocktail

Oral drug cocktail consisting of caffeine (100 mg), dextromethorphan (30 mg), losartan (25 mg), midazolam syrup (2 mg), and omeprazole (20 mg).

Locations(1)

Washington State University College of Pharmacy and Pharmaceutical Sciences

Spokane, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06693960

Related Trials

Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel

NCT066929331 location

Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac

NCT060534111 location